Microbiology Postanalytic Reporting: Critical Values, Documentation, and Public Health

Two principles apply to result interpretation regardless of analyte. Interpret a single outlier in context: a single unexpected quantitative chemistry or hematology result may reflect collection technique, assay imprecision, or specimen handling. Confirm it against the clinical picture and, when the analyte is not a critical or immediately life-threatening result, with a trend or repeat. A valid positive critical microbiology result, such as a malaria smear, PAM wet mount, or cryptococcal antigen, is reportable and actionable under the critical-value policy; do not delay notification while waiting for a trend. Apply Osler’s rule in patients under 60: prefer a single unifying diagnosis that explains every abnormal finding when one plausibly exists.

Antimicrobial susceptibility testing menu selection, CLSI M100 reporting tiers, reporting-policy site filtering, antibiograms, and antimicrobial stewardship remain with the AST module. This module names that ownership and does not reteach those methods.

Critical and urgent values

A critical (panic) value signals a potentially life-threatening result that might otherwise go unnoticed and must reach a caregiver who can act immediately. CLIA requires immediate notification of imminently life-threatening or panic/alert values. Joint Commission and most laboratory policies also require documented verbal read-back. The receiving caregiver repeats the value and the patient’s name, and the laboratory documents the caregiver’s name and title, the date and time, and the read-back. No universal rule determines which analytes have critical thresholds, the threshold values, whether a result must be repeated before notification, how quickly notification must occur, or which caregiver categories may receive one. The laboratory medical director develops these policies with clinical colleagues.

A critical value threatens life and requires a telephone call to a caregiver who can intervene. An urgent result is clinically important and time-sensitive but does not meet that immediate life threat. The laboratory reports it within a defined, shorter turnaround, such as verification and release within a set number of minutes or a direct call without read-back.

Bacteremia and bacterial meningitis are medical emergencies. Continuous-monitoring blood culture systems, rapid molecular panels run on positive blood-culture bottles, and rapid CSF antigen and molecular panels shorten the interval between organism growth and clinician notification.

No external body enumerates the complete critical or urgent list for microbiology. With input from infectious disease, emergency medicine, and nursing, the laboratory director defines both lists and reviews them as organisms and resistance patterns change. The laboratory also monitors notification turnaround time and read-back compliance as quality indicators.

Flags, autoverification, and delta checks

High-volume automated analyzers now release most results directly into the electronic record without human review (autoverification). Flags intercept results that require review. Problem-specimen flags include insufficient volume or chemical interference from lipids, hemoglobin, paraproteins, or bilirubin. Method-escalation flags route ambiguous samples to a more definitive method, as when an automated hematology counter flags possible qualitative abnormalities for smear review. Result-range flags mark a value outside the assay’s validated linear range. Above range, many analyzers auto-dilute and reanalyze; a glucose result flagged above 600 mg/dL and reanalyzed after a 1-in-2 saline dilution that reads 512 mg/dL is reported as 512 × 2 = 1,024 mg/dL.

Gram stains, culture growth, organism identification, and antimicrobial susceptibility interpretations require documented review before release. Autoverification in microbiology is limited to fully validated binary or NAAT results whose rule sets have been approved by the laboratory director, such as a negative screening NAAT with valid internal controls and no instrument flags.

A delta check compares a patient’s current result with previous results before release. Suitable analytes do not fluctuate widely within a person over short intervals; mean corpuscular volume is the classic example. Delta checks catch preanalytic failures, most often specimen mislabeling, far more often than true analytic errors.

Reference intervals and corrected reports

A reference interval is conventionally the central range containing 95% of values from a nondiseased population. By definition, 2.5% of healthy people fall below it and 2.5% above. Reference intervals do not transfer freely between methods or populations. Laboratories are encouraged to establish their own interval per analyte (≥120 nondiseased samples per partition) where practical, or to verify a transferred or manufacturer-supplied interval.

Biologic variability has two components. Interindividual variation is the difference across people. Intraindividual variation is fluctuation within one person over time. The index of individuality equals intraindividual CV divided by interindividual CV. A low index (<0.6) means an individual’s own results cluster in a narrow slice of the wider population interval, so tracking that person’s serial trend detects disease better than comparing a single value to the population range. Glycohemoglobin has a published intraindividual CV of 1.5% and an interindividual CV of 9.6%, giving an index of 1.5 ÷ 9.6 = 0.16. For a patient with a baseline HbA1c of 6.0%, a follow-up value of 6.3% is a 5% change from that individual’s setpoint even though 6.3% falls within a typical population interval.

If volume is insufficient (QNS) for the requested test, report QNS and do not release a result. If a result was already released from an inadequate sample, issue a corrected no-result report.

A routine update from a preliminary to a final report is not a correction. When a released microbiology result is found to be wrong, first identify the error and determine whether it affects a single report or every result touched by the same specimen mix-up, reagent lot, or instrument malfunction. Second, determine whether the original result was already acted on clinically; if it was, notify the ordering provider directly by a documented phone call so that care already underway can be adjusted. Third, issue the corrected report. Label it clearly as a corrected report, display both the original and corrected result with the date and reason for the change, and send it to the ordering provider and any other party responsible for using the result. The laboratory retains both versions. Under CLIA (42 CFR §493.1291(k)), a laboratory that discovers an error in a reported result must promptly notify the ordering provider and any other authorized user, promptly issue a corrected report, and keep copies of both the original and corrected reports.

Microbiology-specific triggers include a misidentification discovered on further work-up, a susceptibility result invalidated by a repeat test or by recognition of a resistance mechanism not accounted for in the original interpretation (for example an isolate initially reported susceptible to a cephalosporin that is later shown to carry an ESBL or carbapenemase), a mixed or contaminated culture originally reported as a single pathogen, and a specimen mix-up between patients. Each corrected report is a quality-system occurrence requiring root-cause investigation.

Documentation practices

Culture-based diagnosis unfolds over days, so microbiology uses staged reports. A preliminary report is issued at the first examination of a culture, such as an initial Gram stain or early colony growth, and is updated as identification and then susceptibility results become available. A final report is issued only after all planned work on the specimen is complete. Each update is a separate dated entry rather than an overwrite of the prior note.

For a culture-based result, the record documents specimen identification and source; date and time of collection and receipt; condition on receipt and, for a rejected specimen, the reason and the person notified; media inoculated and incubation conditions; each culture reading, its date, and the identity of the reader; stain results; identification and susceptibility methods and the interpretive standard applied (for example the CLSI M100 breakpoint table edition in effect); the technologist who performed and reviewed the testing and any pathologist or director review; and the date and time of report release.

Entries are legible, dated, and attributable. A correction to a handwritten or paper record never obliterates the original entry: the original is struck through with a single line so it remains legible, and the correction is dated and initialed. CLIA (42 CFR §493.1105) sets a floor of at least 2 years from the date of reporting for test reports and at least 2 years for the underlying patient test records, quality-control records, and instrument records. Some record types, including histopathology and cytology materials, have longer CLIA-specified retention periods, and an accrediting organization or state law may extend any minimum further. In an electronic laboratory information system, the audit trail is the automatically generated, non-editable log of who entered, modified, verified, and released each result and when.

Infection prevention and public health

Certain organisms and results trigger immediate notification of the facility’s infection prevention and control (IPC) program, independent of any report to the ordering provider. These include MRSA, VRE, carbapenem-resistant Enterobacterales and other carbapenemase-producing organisms, VISA/VRSA, Clostridioides difficile, Mycobacterium tuberculosis complex, respiratory viruses (particularly novel or unsubtypable influenza A), and scabies and lice in a congregate-care setting. A single unexpected finding or a cluster of the same organism or unusual resistance pattern across patients on one unit is reported to IPC as a possible transmission event even when no individual result meets a critical- or urgent-value threshold.

Vancomycin-resistant enterococci carrying acquired vanA/vanB resistance warrant IPC notification because of both the clinical implication and the risk that these transferable genes will spread. Intrinsic, low-level vanC resistance in motile enterococcal species does not carry this transmission risk. Vancomycin-resistant S. aureus isolates are referred to a public-health laboratory for confirmation because automated susceptibility systems do not uniformly flag them reliably. Meningococcal disease triggers coordination with IPC and public health for identification and prophylaxis of household and close contacts.

Separately from IPC, a defined list of conditions is reportable to state and local public-health authorities. CSTE designates and recommends conditions as nationally notifiable in collaboration with CDC; CDC administers the National Notifiable Diseases Surveillance System. Reporting itself is a matter of state law, and a state may require reporting of conditions beyond the national list. Examples spanning microbiology disciplines on the 2026 national list include M. tuberculosis complex, invasive meningococcal disease, Salmonella (including S. Typhi and S. Paratyphi), Shigella, Shiga toxin-producing Escherichia coli, Listeria monocytogenes, Vibrio species, Brucella species, tularemia, anthrax, plague, Lyme disease, rickettsial and ehrlichial infections, syphilis, gonorrhea, Chlamydia trachomatis infection, HIV infection, hepatitis A (acute), hepatitis B and C (acute, chronic, and perinatal), measles, pertussis, and malaria. Coxiella burnetii and Rickettsia prowazekii are additionally HHS select agents. Carbapenemase-producing organisms and VISA/VRSA appear on the current national list as distinct reportable conditions. MRSA and VRE reach public health mainly through mandatory reporting to CDC’s National Healthcare Safety Network by hospitals.

For several of these conditions, state law also requires the laboratory to submit the isolate or original specimen to the state public-health laboratory. A routine clinical laboratory refers a presumptive federal select-agent identification to an LRN reference laboratory and notifies the local or state health department immediately. Brucella abortus, B. melitensis, and B. suis were removed from the HHS/USDA select-agent list effective January 16, 2025; isolates still require BSL-3 rule-out and LRN referral when they cannot be excluded.

Each state’s public-health reporting rule sets the deadline for each condition. Most schemes have an urgent tier that requires immediate telephone notification and a routine tier reported within a state-specified number of business days. Anthrax, plague, meningococcal disease, measles, and suspected bioterrorism agents are commonly in the urgent tier. Electronic laboratory reporting transmits routine-tier results directly from the laboratory information system; urgent-tier results still require immediate telephone notification regardless of ELR capability.

The 2026 national list added COVID-19-associated pediatric mortality and removed dengue-like illness; dengue and severe dengue remain nationally notifiable. Oropouche, added in 2025, is now reported as non-congenital and congenital disease. General SARS-CoV-2 infection is not nationally notifiable in 2026. The current state requirements and CDC’s published NNDSS materials should be checked for each reporting decision.¹

References

1. Centers for Disease Control and Prevention. Notice to data users and publication criteria. National Notifiable Diseases Surveillance System. Reviewed May 14, 2026. Accessed August 31, 2026.